FY2016 EPS Estimates for Seres Therapeutics Inc. (MCRB) Cut by Leerink Swann
Seres Therapeutics Inc. (NASDAQ:MCRB) – Research analysts at Leerink Swann reduced their FY2016 EPS estimates for shares of Seres Therapeutics in a research note issued to investors on Thursday. Leerink Swann analyst J. Schwartz now anticipates that the firm will post earnings per share of ($2.45) for the year, down from their prior estimate of ($2.29). Leerink Swann has a “Buy” rating and a $12.00 price objective on the stock. Leerink Swann also issued estimates for Seres Therapeutics’ Q4 2016 earnings at ($0.77) EPS, FY2017 earnings at ($2.72) EPS and FY2018 earnings at ($2.57) EPS.
Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings data on Thursday, November 10th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.04. The company had revenue of $13.02 million for the quarter, compared to the consensus estimate of $10.38 million. The business’s revenue was up NaN% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.38) earnings per share.
Several other brokerages also recently commented on MCRB. Zacks Investment Research raised Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, October 20th. Cowen and Company reissued a “buy” rating on shares of Seres Therapeutics in a report on Friday, July 29th. HC Wainwright started coverage on Seres Therapeutics in a report on Friday, July 29th. They issued a “buy” rating and a $50.00 target price on the stock. FBR & Co reduced their target price on Seres Therapeutics from $43.00 to $23.00 and set an “outperform” rating on the stock in a report on Friday, August 12th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $20.00 target price on shares of Seres Therapeutics in a report on Monday, August 1st. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $30.00.
Shares of Seres Therapeutics (NASDAQ:MCRB) opened at 12.41 on Monday. The stock’s 50 day moving average price is $11.71 and its 200 day moving average price is $19.69. Seres Therapeutics has a 1-year low of $8.05 and a 1-year high of $44.51. The company’s market capitalization is $500.81 million.
Several hedge funds have recently modified their holdings of the stock. BlackRock Group LTD boosted its stake in shares of Seres Therapeutics by 148.7% in the third quarter. BlackRock Group LTD now owns 10,449 shares of the company’s stock valued at $128,000 after buying an additional 6,248 shares during the last quarter. Cetera Advisor Networks LLC acquired a new stake in shares of Seres Therapeutics during the third quarter valued at approximately $135,000. Birchview Capital LP acquired a new stake in shares of Seres Therapeutics during the second quarter valued at approximately $145,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Seres Therapeutics during the third quarter valued at approximately $171,000. Finally, Rhumbline Advisers boosted its stake in shares of Seres Therapeutics by 1.9% in the third quarter. Rhumbline Advisers now owns 15,732 shares of the company’s stock valued at $193,000 after buying an additional 300 shares during the last quarter. Institutional investors own 76.96% of the company’s stock.
In related news, insider John G. Aunins sold 9,390 shares of the business’s stock in a transaction that occurred on Monday, August 29th. The shares were sold at an average price of $10.87, for a total value of $102,069.30. Following the completion of the transaction, the insider now owns 192,125 shares in the company, valued at approximately $2,088,398.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 41.90% of the stock is currently owned by corporate insiders.
About Seres Therapeutics
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Stock Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related stocks with our FREE daily email newsletter.